5-phenyl[1,2,4]triazines as ligands for GABA-A α2/α3 receptors for treating anxiety or depression
US6969716B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 30, 2004 |
| Grant date | Nov 29, 2005 |
| Priority date | — |
| Expiry date | Jan 30, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/22
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a compound of formula I, or an N-oxide thereof or a pharmaceutically acceptable salt thereof: whereinX1 represents hydrogen, halogen, C1-6 alkyl, trifluoromethyl or C1-6 alkoxy;X2 represents hydrogen or halogen;Z represents hydrogen, halogen, cyano, cyanomethyl, trifluoromethyl, nitro, hydroxy, hydroxy(C1-6)alkyl, C1-6 alkoxy, C1-6 alkoxy(C1-6)alkyl, trifluoromethoxy, trifluoromethylthio, trifluoromethanesulfinyl, formyl, C2-6 alkoxycarbonyl, oxopyrrolidinyl, or an optionally substituted aryl, heteroaryl or heteroaryl(C1-6)alkoxy group; andR1 represents aryl or heteroaryl, either of which groups may be optionally substituted;pharmaceutical compositions comprising it, its use in therapy and methods of treatment of anxiety and/or depression using it.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.